Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Eureka
Emeryville, California, United Stateseurekatherapeutics.com ↗
- Ownership
- Private
- Employees
- ~67
- Development stage
- Other
01
Overview
Eureka Therapeutics is running US-based Phase 1/2 trials for T cell therapies targeting AFP and GPC3 in advanced liver cancer; interim results and broader pipeline details not publicly disclosed as of August 2025
- Therapeutic areas
- Oncology
- Modalities
- T cell therapyAntibodyMonoclonal antibody
- Industry
- Biotech
02
Partnerships
Partners and collaborators in solid tumor research (specifics not named as of January 2025)
Beyond the preview
Go deeper on Eureka.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eureka.